Skip to content

Study · Case report or series · n = 1 · 2025

3 results

Short-Term Semaglutide Improves Safety in High Body Weight Recipients Undergoing Living Donor Liver Transplant: A Case Report.

Cheng SM, Lai Y, Huang RY, Lee WC, Lee CF, Wu TJ

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation1 Dec 2025

PMID41578754 (opens in a new tab)DOI10.6002/ect.2025.0244 (opens in a new tab)PepBankPUB-41578754
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In an obese liver transplant recipient, oral semaglutide was followed by a weight loss of 10 kg over 19 days.

    In plain wordsOne obese patient waiting for a liver transplant lost 10 kg in 19 days on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreasePretransplant weight loss
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight loss
    10 kg
    19 days

    Source sentences

    Summary
    The patient experienced a significant weight loss of 10 kg during a period of 19 days
    1 context sentence
    Summary · context
    This case report describes the use of oral semaglutide, a glucagon-like peptide-1 receptor agonist, to faci-litate pretransplant weight loss in an obese patient (body mass index 39.1, in kg/m2) undergoing living donor liver transplant.
  2. 02HumanCase report or seriesEfficacy outcome

    In an obese liver transplant recipient, the graft-to-recipient weight ratio improved from 0.66% to 0.786% after semaglutide-induced weight loss.

    In plain wordsIn one patient, weight loss on semaglutide improved the match between donor liver size and the patient's weight.

    Peptide
    Semaglutide
    Outcome
    IncreaseGraft-to-recipient weight ratio
    Study

    n = 1

    Outcome group
    Body weight · Liver
    Studied dose
    Dose not stated

    Measurements

    Graft-to-recipient weight ratio
    0.66%
    before
    Graft-to-recipient weight ratio
    0.786%
    after

    Source sentences

    Summary
    which improved the graft-to-recipient weight ratio (from 0.66% to 0.786%)
    1 context sentence
    Summary · context
    This case report describes the use of oral semaglutide, a glucagon-like peptide-1 receptor agonist, to faci-litate pretransplant weight loss in an obese patient (body mass index 39.1, in kg/m2) undergoing living donor liver transplant.
  3. 03HumanCase report or seriesSafety outcome

    In an obese recipient who took semaglutide before living donor liver transplant, the procedure was uneventful with no postoperative issues.

    In plain wordsOne patient who took semaglutide before a liver transplant had an uneventful operation with no problems afterwards.

    Peptide
    Semaglutide
    Outcome
    No significant changePostoperative course
    Study

    n = 1

    Outcome group
    Adverse events · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    resulted in an uneventful living donor liver transplant procedure with no postoperative issues.
    1 context sentence
    Summary · context
    This case report describes the use of oral semaglutide, a glucagon-like peptide-1 receptor agonist, to faci-litate pretransplant weight loss in an obese patient (body mass index 39.1, in kg/m2) undergoing living donor liver transplant.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.